Using the established protocol [27], BMB from 45 controls, 69 MDS, and 33 sAML patients were analyzed by simultaneous staining for the markers CD3, CD8, FOXP3, MUM1p, and CD34, combined with nuclear staining using DAPI as representatively shown in Figure 1A. Patient characteristics are summarized in Table 1. The gene discussed is FOXP3; the disease is myelodysplastic syndrome.